€5.29
Your prediction
Aurinia Pharmaceuticals Inc. Stock
Pros and Cons of Aurinia Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Aurinia Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. | 0.340% | 13.483% | 12.686% | -46.254% | -35.043% | -49.725% | -8.250% |
| Promis Neurosciences Inc. | 10.320% | -0.581% | -2.286% | -65.385% | 71.859% | -74.091% | -84.921% |
| InMed Pharmaceuticals Inc. | 12.900% | 8.537% | 3.488% | -78.222% | -22.384% | -99.527% | -99.890% |
| Resverlogix Corp | -7.590% | 0.000% | 0.000% | -56.548% | -15.116% | -93.917% | -98.386% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon a first glance at the financials of Aurinia Pharma, a company within the Biotechnology & Medical Research industry, it is clear that they have experienced fluctuations within their financial performance over the past few years. The company's balance sheet, cash flow, and income statement show some promising elements, as well as a few areas of concern.
*Pros: *
Growing Total Assets and Stockholder Equity: Over the past three years, Aurinia Pharma has seen a steady growth in their total assets, from $463.66 million in 2020 to $470.86 million in 2022. This growth signifies an expanding company, which is a positive sign for investors. Additionally, the total stockholder equity has increased from $407.75 million in 2020 to $405.43 million in 2022, highlighting a robust financial foundation for the company.
Comments
News
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024